Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD

BACKGROUND: The CARD study demonstrated superiority of cabazitaxel over abiraterone/enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel and progressed ≤12 months on the alternative androgen-receptor-targeted agent (ARTA). The objective w...

Descripción completa

Detalles Bibliográficos
Autores principales: de Wit, Ronald, Freedland, Stephen J., Oudard, Stephane, Marinov, Georgi, Capart, Philippe, Combest, Austin J., Peterson, Ryan, Ozatilgan, Ayse, Morgans, Alicia K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023563/
https://www.ncbi.nlm.nih.gov/pubmed/35039605
http://dx.doi.org/10.1038/s41391-021-00487-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023563/
https://www.ncbi.nlm.nih.gov/pubmed/35039605
http://dx.doi.org/10.1038/s41391-021-00487-1

Ejemplares similares